Consideraciones sobre el abordaje terapéutico en pacientes con diabetes mellitus y enfermedad cardiovascular
Texto completo:
PDFResumen
Conocer las tendencias de las enfermedades crónicas no transmisibles, permite a los profesionales establecer acciones de salud que disminuyan la mortalidad por diabetes mellitus, enfermedad cardiovascular y cerebrovascular; afecciones que, con frecuencia, constituyen causas de muerte en la población. Las intervenciones terapéuticas para prevenir, o al menos retrasar, la aparición de complicaciones en las personas con diabetes, se han hecho más intensivas, y las metas de control más estrictas. Un ejemplo es el uso de fármacos como estrategia de prevención cardiovascular; sin embargo, a pesar de ello, los pacientes mantienen un riesgo aumentado en 2-4 veces de enfermedades cardiovasculares y la mortalidad es 1,5-3,6 veces mayor respecto a la población general. Por eso, la búsqueda de estrategias para predecir un evento vascular con mayor exactitud, a partir de la evaluación del riesgo cardiovascular global y de la presencia de aterosclerosis subclínica, constituye actualmente un desafío para los profesionales de la salud.
Referencias
Guamán C, Acosta W, Alvarez C, Hasbum B. Diabetes y enfermedad cardiovascular. Rev Urug Cardiol. 2021;36(1):7-18. DOI: https://doi.org/10.29277/cardio.36.1.4
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI: https://doi.org/10.1093/eurheartj/ehz486
International Diabetes Federation. IDF Diabetes Atlas - 9th Edition [Internet]. Bruselas: International Diabetes Federation [citado 26 May 2022]; 2019. Disponible en: https://diabetesatlas.org/atlas/ninth-edition/
Rawshani A, Sattar N, Franzén S, Rawshani A, Hattersley AT, Svensson AM, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477-86. DOI: https://doi.org/10.1016/s0140-6736(18)31506-x
Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration: Gnatiuc L, Herrington WG, Halsey J, Tuomilehto J, Fang X, Kim HC, et al. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018;6(7):538-46. DOI: https://doi.org/10.1016/s2213-8587(18)30079-2
Álvarez-Vázquez L, Arnold-Domínguez Y. Envejecimiento poblacional y efecto en la diabetes mellitus en Cuba. Rev Cient. 2016;26(1):71-7. DOI: https://doi.org/10.54495/Rev.Cientifica.v26i1.83
Ministerio de Salud Pública. Anuario Estadístico de Salud 2019. La Habana: Dirección de Registros Médicos y Estadísticas de Salud; 2020. Enlace: https://salud.msp.gob.cu/wp-content/Anuario/Anuario-2020.pdf
Vega Jiménez J, Verano Gómez NC, Rodríguez López JF, Labrada González E, Sánchez Garrido A, Espinosa Pire LN. Factores cardioaterogénicos y riesgo cardiovascular en diabéticos tipo 2 hospitalizados. Rev Cuban Med Mil [Internet]. 2018 [citado 30 May 2022];47(2):133-45. Disponible en: https://revmedmilitar.sld.cu/index.php/mil/article/view/119/184
Ernande L, Audureau E, Jellis CL, Bergerot C, Henegar C, Sawaki D, et al. Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus. J Am Coll Cardiol. 2017;70(14):1704-16. DOI: https://doi.org/10.1016/j.jacc.2017.07.792
Valenti V, Hartaigh BÓ, Cho I, Schulman-Marcus J, Gransar H, Heo R, et al. Absence of Coronary Artery Calcium Identifies Asymptomatic Diabetic Individuals at Low Near-Term But Not Long-Term Risk of Mortality: A 15-Year Follow-Up Study of 9715 Patients. Circ Cardiovasc Imaging [Internet]. 2016 [citado 2 Jun 2022 ];9(2):e003528. Disponible en: https://doi.org/10.1161/circimaging.115.003528
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603-15. DOI: https://doi.org/10.1001/jama.2014.18574
Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34(5):575-84. DOI: https://doi.org/10.1016/j.cjca.2017.12.005
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI: https://doi.org/10.1093/eurheartj/ehy339
Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, et al. Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group. Sports Med. 2018;48(8):1781-97. DOI: https://doi.org/10.1007/s40279-018-0930-4
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. DOI: https://doi.org/10.1056/nejmoa1603827
Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. J Am Heart Assoc. 2017;6(6):e004007. DOI: https://doi.org/10.1161/jaha.116.004007
ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529-39. DOI: https://doi.org/10.1056/nejmoa1804988
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI: https://doi.org/10.1093/eurheartj/ehz425
Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740-51. DOI: https://doi.org/10.7326/m15-2650
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-66. DOI: https://doi.org/10.1001/jama.2019.13772
Bain S, Druyts E, Balijepalli C, Baxter CA, Currie CJ, Das R, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19(3):329-35. DOI: https://doi.org/10.1111/dom.12821
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89. DOI: https://doi.org/10.1016/s0140-6736(05)67528-9
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71. DOI: https://doi.org/10.1056/nejmoa072761
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-44. DOI: https://doi.org/10.1056/nejmoa1607141
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51. DOI: https://doi.org/10.1056/nejmoa1901118
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. DOI: https://doi.org/10.1056/nejmoa1504720
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. DOI: https://doi.org/10.1056/nejmoa1611925
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. (DECLARE–TIMI 58 Investigators). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57. DOI: https://doi.org/10.1056/nejmoa1812389
Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422-34. DOI: https://doi.org/10.1016/j.jacc.2019.11.031
Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, et al. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes Obes Metab. 2019;21(7):1625-33. DOI: https://doi.org/10.1111/dom.13699
Arnold SV, Lipska KJ, Inzucchi SE, Li Y, Jones PG, McGuire DK, Goyal A, Stolker JM, Lind M, Spertus JA, Kosiborod M. The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. BMJ Open Diabetes Res Care [Internet]. 2014 [citado 6 Jun 2022];2(1):e000046. Disponible en: https://doi.org/10.1136/bmjdrc-2014-000046
Zhao YT, Weng CL, Chen ML, Li KB, Ge YG, Lin XM, et al. Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials. Heart. 2010;96(20):1622-6. DOI: https://doi.org/10.1136/hrt.2010.194563
Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650-61. DOI: https://doi.org/10.1093/eurheartj/ehi199
NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-97. DOI: https://doi.org/10.1056/nejmoa0810625
Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res. 2018;15(6):494-503. DOI: https://doi.org/10.1177/1479164118794619
Demant MN, Gislason GH, Køber L, Vaag A, Torp-Pedersen C, Andersson C. Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study. Diabetologia. 2014;57(8):1595-600. DOI: https://doi.org/10.1007/s00125-014-3259-z
Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718-27, 1727a-1727c. DOI: https://doi.org/10.1093/eurheartj/ehv134
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333-40. DOI: https://doi.org/10.1016/s2213-8587(17)30087-6
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. DOI: https://doi.org/10.1056/nejmoa1911303
Pallisgaard JL, Schjerning AM, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, et al. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur J Prev Cardiol. 2016;23(6):621-7. DOI: https://doi.org/10.1177/2047487315599892
Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56-62. DOI: https://doi.org/10.1016/j.amjcard.2011.03.004
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI: https://doi.org/10.1093/eurheartj/ehaa612
Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace. 2014;16(9):1257-83. DOI: https://doi.org/10.1093/europace/euu194
Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34(29):2281-329. DOI: https://doi.org/10.1093/eurheartj/eht150
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867. DOI: https://doi.org/10.1093/eurheartj/ehv316
Enlaces refback
- No hay ningún enlace refback.
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
